查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1747731

現實世界數據的全球市場

Real World Data
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球真實世界數據市場規模將達到 54 億美元

全球現實世界數據市場規模預計在2024年為22億美元，預計到2030年將達到54億美元，2024年至2030年的複合年成長率為15.9%。報告分析的細分市場之一「服務組件」預計複合年成長率為17.7%，到分析期結束時將達到37億美元。資料集組件細分市場在分析期間內的複合年成長率預計為12.5%。

美國市場規模估計為 5.905 億美元，中國市場預計複合年成長率為 14.9%

美國現實世界數據市場規模預計在2024年達到5.905億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到8.354億美元，在2024-2030年的分析期內，複合年成長率將達到14.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為14.8%和13.5%。在歐洲，預計德國市場的複合年成長率將達到11.4%。

全球「真實世界數據」市場—主要趨勢與促進因素摘要

現實世界的數據會重塑基於證據的決策的未來嗎？

真實世界數據 (RWD) 正在成為醫療創新的基石，將臨床研究範式從受控臨床試驗轉變為從真實世界患者體驗中提取的證據。來自電子健康記錄(EHR)、保險理賠、病患登記、穿戴式裝置和行動醫療應用程式的 RWD 能夠洞察不同族群的治療效果、安全性、依從性和療效。這使得監管機構、付款人和製藥公司能夠了解治療在受控環境之外的效果，從而支持自適應臨床試驗、藥物安全檢測和基於價值的報銷模式。在公共衛生領域，RWD 可以為政策決策提供資訊，並即時追蹤病情進展。隨著醫療保健系統推動個人化、數據主導的醫療服務，RWD 正在成為一種策略性資產，將患者行為與可操作的臨床洞察聯繫起來。

什麼技術可以最大程度發揮 RWD 的潛力？

健康數據的爆炸性成長和數據分析技術的進步正在釋放現實世界數據利用的新領域。雲端運算、巨量資料平台和人工智慧演算法正在實現對大量不同資料集的提取、協調和即時分析。自然語言處理 (NLP) 從臨床記錄和非結構化 EHR 資料中提取結構化見解。 HL7 FHIR 等互通性框架正在改善跨系統和相關人員的資料共用。人們正在探索使用區塊鏈來確保數據來源、安全性和患者同意。這些技術正在將 RWD 從被動記錄轉變為推動藥物開發、人口健康策略和個人化治療途徑的動態資源。隨著資料生態系統的成熟，RWD 的品質、可靠性和監管可接受性也在不斷提高。

整個醫療生態系統的相關人員如何接受 RWD？

製藥公司正在將 RWD 納入藥物生命週期的所有階段，從臨床試驗設計和地點選擇到上市後監測和標籤擴展。 FDA 和 EMA 等監管機構越來越依賴 RWD 來支持核准和監測真實世界人群的安全性。付款人正在使用 RWD 來評估成本效益和確定覆蓋範圍。醫療保健提供者正在應用 RWD 分析來改善護理協調、減少醫院再入院率和最佳化治療通訊協定。患者也正在成為關鍵的相關人員，他們透過應用程式和穿戴式裝置提供數據，並要求透明度和控制力。圍繞 RWD 的相關人員利益的融合正在促進夥伴關係、數據聯盟和創新中心，加速將健康數據轉化為健康影響。

什麼推動了全球現實世界數據市場的成長？

現實世界數據市場的成長得益於健康數據基礎設施的進步、監管支持以及最終用戶對個人化、基於價值的護理的需求。從技術上講，改進的分析工具、雲端擴充性和互通性標準使我們能夠從龐大且多樣化的資料集中獲取切實可行的見解。從最終用戶的觀點來看，生物製藥公司、付款人和醫療系統正在利用 RWD 來提高效率、最佳化結果並滿足不斷變化的護理期望。數位健康工具、穿戴式裝置和病人參與平台的使用增加正在產生更豐富的資料集以供分析。監管機構在決策和政策制定中支持 RWD 的努力也增加了市場的可信度。隨著全球醫療保健系統從數量轉向價值，從現實世界證據中獲得有意義見解的能力正在成為關鍵的競爭優勢。

部分

組件（服務、資料集）；應用（藥物開發和核准、市場准入和報銷/研究資格、上市後監測、臨床研究、其他應用）；最終用途（製藥和醫療設備公司、付款人、醫療保健提供者、政府機構、其他最終用途）

受訪企業範例（共42家）

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP35640

Global Real World Data Market to Reach US$5.4 Billion by 2030

The global market for Real World Data estimated at US$2.2 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 15.9% over the analysis period 2024-2030. Services Component, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Datasets Component segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$590.5 Million While China is Forecast to Grow at 14.9% CAGR

The Real World Data market in the U.S. is estimated at US$590.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$835.4 Million by the year 2030 trailing a CAGR of 14.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.8% and 13.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global "Real World Data" Market - Key Trends & Drivers Summarized

Is Real World Data Reshaping The Future Of Evidence-Based Decision Making?

Real World Data (RWD) is becoming a cornerstone of healthcare innovation, shifting the paradigm from controlled clinical trials to evidence drawn from real-life patient experiences. Sourced from electronic health records (EHRs), insurance claims, patient registries, wearables, and mobile health apps, RWD provides insights into treatment efficacy, safety, adherence, and outcomes across diverse populations. It allows regulators, payers, and pharmaceutical companies to understand how therapies perform outside controlled environments, supporting adaptive clinical trials, pharmacovigilance, and value-based reimbursement models. In public health, RWD informs policy decisions and tracks disease progression in real-time. As healthcare systems push for personalized, data-driven care, RWD is emerging as a strategic asset that links patient behavior with actionable clinical insights.

What Technologies Are Unlocking The Full Potential Of RWD?

The explosion of health data and advances in data analytics are unlocking new frontiers for Real World Data utilization. Cloud computing, big data platforms, and AI algorithms are enabling the ingestion, harmonization, and real-time analysis of massive, heterogeneous datasets. Natural language processing (NLP) is extracting structured insights from clinical notes and unstructured EHR data. Interoperability frameworks like HL7 FHIR are improving data sharing across systems and stakeholders. Blockchain is being explored to ensure data provenance, security, and patient consent. These technologies are transforming RWD from passive records into dynamic resources that fuel drug development, population health strategies, and personalized treatment pathways. As data ecosystems mature, the quality, reliability, and regulatory acceptance of RWD are also improving.

How Are Stakeholders Across The Healthcare Ecosystem Embracing RWD?

Pharmaceutical companies are integrating RWD into all stages of the drug lifecycle-from trial design and site selection to post-market surveillance and label expansion. Regulators like the FDA and EMA are increasingly relying on RWD to support approvals and monitor safety in real-world populations. Payers are using RWD to assess cost-effectiveness and inform coverage decisions. Healthcare providers are applying RWD analytics to improve care coordination, reduce readmissions, and optimize treatment protocols. Patients are also becoming key stakeholders, contributing data through apps and wearable devices while demanding transparency and control. The convergence of stakeholder interests around RWD is fostering partnerships, data consortiums, and innovation hubs that accelerate the transformation of health data into health impact.

What’s Accelerating Growth In The Real World Data Market Globally?

The growth in the Real World Data market is driven by advancements in health data infrastructure, regulatory support, and end-user demand for personalized, value-based care. Technologically, improved analytics tools, cloud scalability, and interoperability standards are enabling actionable insights from vast and diverse datasets. From an end-use perspective, biopharma, payers, and health systems are leveraging RWD to drive efficiency, optimize outcomes, and meet evolving care expectations. Increased use of digital health tools, wearables, and patient engagement platforms is generating richer datasets for analysis. Regulatory initiatives supporting RWD in decision-making and policy formulation are also boosting market credibility. As global healthcare systems transition from volume to value, the ability to derive meaningful insights from real-world evidence is becoming a key competitive differentiator.

SCOPE OF STUDY:

The report analyzes the Real World Data market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Services, Datasets); Application (Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research, Other Applications); End-Use (Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers, Government Agencies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Aetion, Inc.
  • Atropos Health
  • BEKHealth
  • Cerner Corporation
  • Clarify Health Solutions
  • ConcertAI
  • Datavant
  • Evidera, Inc.
  • Flatiron Health, Inc.
  • HealthVerity
  • IBM Corporation
  • ICON plc
  • IQVIA Holdings Inc.
  • K2view
  • Merative
  • Mount Sinai Health System
  • Optum, Inc.
  • Palantir Technologies Inc.
  • PAREXEL International Corporation
  • SAS Institute Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Real World Data - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Accelerated Shift Toward Evidence-Based Healthcare Models Spurs Use of Real World Data
    • Increased Regulatory Acceptance of RWD in Drug Approvals and Label Expansions Drives Market Relevance
    • Rising Use of EHR, Claims, and Patient-Reported Outcomes Data Expands Data Variety
    • Growth in Value-Based Care and Health Economics Research Strengthens Demand for Real-World Evidence
    • AI and Advanced Analytics Integration Enhances Data Utility in Clinical and Commercial Strategy
    • Collaborations Between Pharma, Payers, and Tech Firms Propel RWD Platform Development
    • Decentralized Clinical Trials and Virtual Health Models Expand Demand for Real-Time Patient Data
    • Regulatory Pressure for Post-Market Surveillance and Pharmacovigilance Supports Adoption
    • Privacy Concerns and Data Governance Requirements Present Compliance Challenges
    • Global Expansion of Health Data Infrastructure Opens Regional Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Real World Data Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Real World Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Datasets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Datasets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Government Agencies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical & Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Drug Development & Approvals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Drug Development & Approvals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Market Access & Reimbursement / Coverage Decisions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Market Access & Reimbursement / Coverage Decisions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Post-Market Surveillance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Post-Market Surveillance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • CHINA
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Real World Data by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Real World Data by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Real World Data Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Real World Data by Component - Services and Datasets - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Real World Data by Component - Percentage Breakdown of Value Sales for Services and Datasets for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Real World Data by End-Use - Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Real World Data by End-Use - Percentage Breakdown of Value Sales for Healthcare Providers, Government Agencies, Other End-Uses, Pharmaceutical & Medical Device Companies and Healthcare Payers for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Real World Data by Application - Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Real World Data by Application - Percentage Breakdown of Value Sales for Drug Development & Approvals, Market Access & Reimbursement / Coverage Decisions, Post-Market Surveillance, Clinical Research and Other Applications for the Years 2025 & 2030

IV. COMPETITION